- Home
- KALV
as 03-28-2025 4:00pm EST
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 563.1M | IPO Year: | N/A |
| Target Price: | $24.83 | AVG Volume (30 days): | 619.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.30 - $15.50 | Next Earning Date: | 03-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of KalVista Pharmaceuticals Inc. (KALV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Mar 6 '25 | Sell | $11.97 | 6,669 | $79,827.93 | 287,811 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Feb 22 '25 | Sell | $10.02 | 2,394 | $23,987.88 | 102,940 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Feb 21 '25 | Sell | $10.02 | 1,918 | $19,218.36 | 93,952 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Feb 17 '25 | Sell | $9.82 | 5,104 | $50,142.72 | 287,811 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Feb 17 '25 | Sell | $9.82 | 2,601 | $25,552.74 | 93,952 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Feb 17 '25 | Sell | $9.82 | 3,125 | $30,700.62 | 102,940 | |
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Feb 12 '25 | Buy | $9.28 | 161,700 | $1,498,661.00 | 5,217,285 | |
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Feb 7 '25 | Buy | $9.20 | 104,489 | $967,144.93 | 5,217,285 | |
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Jan 30 '25 | Buy | $8.96 | 70,023 | $621,628.02 | 5,217,285 |
Latest KalVista Pharmaceuticals Inc. News
KALV Breaking Stock News: Dive into KALV Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
4 days ago
KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial
MT Newswires
5 days ago
KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial
Business Wire
5 days ago
KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial
Business Wire
18 days ago
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
Business Wire
20 days ago
KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema
Business Wire
a month ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
a month ago
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
Business Wire
a month ago
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
Compare KALV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KALV KalVista Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.